CAB-EGFR

N/A

Report date: 2026/03/19 16:59:34

Base Information

Drug NameCAB-EGFR

Drug Alias NameEGFR x CAB-CD3 bispecific mAb (BioAtla)anti-CD3/anti-EGFR bispecific T-cell engager (BioAtla)CAB-EGFR

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpidermal growth factor receptor erbB1 modulators

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBioAtla Inc

China Registration ClassN/A

Develop Information

Active CompaniesBioAtla Inc

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A